Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with advanced non–small-cell lung cancer (NSCLC) by demonstrating significantly better outcomes and tolerability than conventional chemotherapy.

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

Wallace Akerley, MDProfessor of Medicine Thoracic Oncology Huntsman Cancer Institute at University of Utah Salt Lake City, UT Katie Kerrigan, DO Assistant Professor of Internal Medicine Division of Medical Oncology Huntsman Cancer Institute at University of Utah Salt Lake City, UT Introduction Immune checkpoint inhibitors (ICIs) have revolutionized the treatment [ Read More ]